Kolinsky Wealth Management LLC Has $603,000 Holdings in Abbott Laboratories (NYSE:ABT)

Kolinsky Wealth Management LLC grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 4.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 5,334 shares of the healthcare product maker’s stock after purchasing an additional 242 shares during the period. Kolinsky Wealth Management LLC’s holdings in Abbott Laboratories were worth $603,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ABT. Regent Peak Wealth Advisors LLC lifted its position in shares of Abbott Laboratories by 2.0% during the fourth quarter. Regent Peak Wealth Advisors LLC now owns 4,873 shares of the healthcare product maker’s stock valued at $551,000 after purchasing an additional 97 shares in the last quarter. Tallon Kerry Patrick bought a new position in shares of Abbott Laboratories during the 4th quarter worth approximately $200,000. Capital & Planning LLC boosted its stake in shares of Abbott Laboratories by 1.2% in the 4th quarter. Capital & Planning LLC now owns 8,673 shares of the healthcare product maker’s stock worth $981,000 after buying an additional 100 shares during the last quarter. Zhang Financial LLC grew its holdings in shares of Abbott Laboratories by 33.6% in the fourth quarter. Zhang Financial LLC now owns 4,674 shares of the healthcare product maker’s stock valued at $529,000 after acquiring an additional 1,176 shares in the last quarter. Finally, LaFleur & Godfrey LLC increased its position in shares of Abbott Laboratories by 23.5% during the fourth quarter. LaFleur & Godfrey LLC now owns 82,443 shares of the healthcare product maker’s stock valued at $9,325,000 after acquiring an additional 15,692 shares during the last quarter. 75.18% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. UBS Group boosted their price objective on Abbott Laboratories from $146.00 to $148.00 and gave the stock a “buy” rating in a research report on Thursday, January 23rd. Barclays increased their price target on shares of Abbott Laboratories from $158.00 to $159.00 and gave the company an “overweight” rating in a research report on Thursday, April 17th. StockNews.com lowered shares of Abbott Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 12th. Jefferies Financial Group boosted their target price on shares of Abbott Laboratories from $135.00 to $137.00 and gave the company a “hold” rating in a research note on Thursday, April 17th. Finally, Bank of America raised their price target on shares of Abbott Laboratories from $133.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, March 10th. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $142.59.

Abbott Laboratories Stock Down 0.3%

ABT stock opened at $135.18 on Wednesday. The stock has a 50-day simple moving average of $129.57 and a two-hundred day simple moving average of $124.37. Abbott Laboratories has a twelve month low of $99.71 and a twelve month high of $141.23. The firm has a market capitalization of $235.19 billion, a PE ratio of 17.67, a PEG ratio of 2.52 and a beta of 0.74. The company has a quick ratio of 1.14, a current ratio of 1.60 and a debt-to-equity ratio of 0.32.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, April 16th. The healthcare product maker reported $1.09 EPS for the quarter, beating the consensus estimate of $1.07 by $0.02. Abbott Laboratories had a net margin of 31.95% and a return on equity of 20.74%. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.38 billion. On average, equities analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, May 15th. Investors of record on Tuesday, April 15th were given a $0.59 dividend. The ex-dividend date of this dividend was Tuesday, April 15th. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.75%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 30.61%.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, EVP Andrea F. Wainer sold 949 shares of Abbott Laboratories stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $138.17, for a total transaction of $131,123.33. Following the completion of the sale, the executive vice president now directly owns 74,381 shares in the company, valued at $10,277,222.77. The trade was a 1.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Lisa D. Earnhardt sold 91,167 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $133.82, for a total transaction of $12,199,967.94. Following the completion of the transaction, the executive vice president now directly owns 71,928 shares in the company, valued at $9,625,404.96. The trade was a 55.90% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 95,278 shares of company stock valued at $12,745,859. Company insiders own 0.46% of the company’s stock.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.